Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CASTLE BIOSCIENCES INCCSTL · Entity 359 | Director · Pres. & Chief Exec. Officer | October 05, 2026 | October 07, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CASTLE BIOSCIENCES INC
Report date October 05, 2026 · Filed October 07, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 21,064 |
Ending reported balance
After 2026-10-05 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-10-05 · Exercise / conversion · Acquired 8,165 · Balance 29,644 F1: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on June 2, 2026. Row 2 · 2026-10-05 · Sale · Disposed 8,580 · Balance 21,064 F1: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on June 2, 2026. F2: This transaction was executed in multiple trades at prices ranging from $35.310 to $35.965, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |
| Common StockSEC Table I · non-derivative | IndirectBy The Maetzold Descendants 2020 Trust | 8,038 |
Reported balance
After 2026-10-05 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2026-10-05 · Sale · Disposed 3,198 · Balance 8,038 F1: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on June 2, 2026. F2: This transaction was executed in multiple trades at prices ranging from $35.310 to $35.965, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F3: Held by The Maetzold Descendants 2020 Trust of which the Reporting Person's spouse is the trustee and the Reporting Person's spouse and their children are beneficiaries. |
| Common StockSEC Table I · non-derivative | IndirectBy Derek Maetzold 2020 Irrevocable Trust | 6,832 |
Reported balance
After 2026-10-05 transaction · row 4
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 4 · 2026-10-05 · Sale · Disposed 2,718 · Balance 6,832 F1: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on June 2, 2026. F2: This transaction was executed in multiple trades at prices ranging from $35.310 to $35.965, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F4: Held by Derek Maetzold 2020 Irrevocable Trust of which the Reporting Person is the trustee and his children are beneficiaries. |
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.39 · Expires 2028-05-09 | Direct | 0 |
Reported balance
After 2026-10-05 transaction · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · 2026-10-05 · Exercise / conversion · Disposed 8,165 · Balance 0 F1: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on June 2, 2026. F13: The shares subject to the option are fully vested. |
| Common StockSEC Table I · non-derivative | IndirectBy The Maetzold 2018 Remainder Trust FBO Emily Carol Kirk | 11,256 |
Reported balance
Holding disclosure · report date 2026-10-05 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 11,256 F5: Held by The Maetzold 2018 Remainder Trust FBO Emily Carol Kirk of which the Reporting Person is the trustee and his child is the beneficiary. |
| Common StockSEC Table I · non-derivative | IndirectBy The Maetzold 2018 Remainder Trust FBO Hannah Elizabeth Maetzold | 11,256 |
Reported balance
Holding disclosure · report date 2026-10-05 · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · Balance 11,256 F6: Held by The Maetzold 2018 Remainder Trust FBO Hannah Elizabeth Maetzold of which the Reporting Person is the trustee and his child is the beneficiary. |
| Common StockSEC Table I · non-derivative | IndirectBy The Maetzold 2018 Remainder Trust FBO John Derek Maetzold | 11,256 |
Reported balance
Holding disclosure · report date 2026-10-05 · row 7
Holding and transaction disclosures are not merged.
1 source rowRow 7 · Balance 11,256 F7: Held by The Maetzold 2018 Remainder Trust FBO John Derek Maetzold of which the Reporting Person is the trustee and his child is the beneficiary. |
| Common StockSEC Table I · non-derivative | IndirectBy The Maetzold 2018 Remainder Trust FBO Peter Douglas Maetzold | 11,256 |
Reported balance
Holding disclosure · report date 2026-10-05 · row 8
Holding and transaction disclosures are not merged.
1 source rowRow 8 · Balance 11,256 F8: Held by The Maetzold 2018 Remainder Trust FBO Peter Douglas Maetzold of which the Reporting Person is the trustee and his child is the beneficiary. |
| Common StockSEC Table I · non-derivative | IndirectBy DJM Grantor Retained Annuity Trust No. 6 | 11,963 |
Reported balance
Holding disclosure · report date 2026-10-05 · row 9
Holding and transaction disclosures are not merged.
1 source rowRow 9 · Balance 11,963 F9: Held by DJM Grantor Retained Annuity Trust No. 6 of which the Reporting Person is the trustee and the beneficiaries are The Maetzold 2018 Remainder Trust FBO John Derek Maetzold, The Maetzold 2018 Remainder Trust FBO Emily Carol Kirk, The Maetzold 2018 Remainder Trust FBO Peter Douglas Maetzold and The Maetzold 2018 Remainder Trust FBO Hannah Elizabeth Maetzold. |
| Common StockSEC Table I · non-derivative | IndirectBy DJM Grantor Retained Annuity Trust No. 7 | 27,862 |
Reported balance
Holding disclosure · report date 2026-10-05 · row 10
Holding and transaction disclosures are not merged.
1 source rowRow 10 · Balance 27,862 F10: Held by DJM Grantor Retained Annuity Trust No. 7 of which the Reporting Person is the trustee and beneficiary. |
| Common StockSEC Table I · non-derivative | IndirectBy DJM Grantor Retained Annuity Trust No. 8 | 40,935 |
Reported balance
Holding disclosure · report date 2026-10-05 · row 11
Holding and transaction disclosures are not merged.
1 source rowRow 11 · Balance 40,935 F11: Held by DJM Grantor Retained Annuity Trust No. 8 of which the Reporting Person is the trustee and beneficiary. |
| Common StockSEC Table I · non-derivative | IndirectDJM Grantor Retained Annuity Trust No. 9 | 23,216 |
Reported balance
Holding disclosure · report date 2026-10-05 · row 12
Holding and transaction disclosures are not merged.
1 source rowRow 12 · Balance 23,216 F12: Held by DJM Grantor Retained Annuity Trust No. 9 of which the Reporting Person is the trustee and beneficiary. |
Filing footnotes · ownership attribution and instrument terms
F1: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on June 2, 2026.
F2: This transaction was executed in multiple trades at prices ranging from $35.310 to $35.965, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F3: Held by The Maetzold Descendants 2020 Trust of which the Reporting Person's spouse is the trustee and the Reporting Person's spouse and their children are beneficiaries.
F4: Held by Derek Maetzold 2020 Irrevocable Trust of which the Reporting Person is the trustee and his children are beneficiaries.
F5: Held by The Maetzold 2018 Remainder Trust FBO Emily Carol Kirk of which the Reporting Person is the trustee and his child is the beneficiary.
F6: Held by The Maetzold 2018 Remainder Trust FBO Hannah Elizabeth Maetzold of which the Reporting Person is the trustee and his child is the beneficiary.
F7: Held by The Maetzold 2018 Remainder Trust FBO John Derek Maetzold of which the Reporting Person is the trustee and his child is the beneficiary.
F8: Held by The Maetzold 2018 Remainder Trust FBO Peter Douglas Maetzold of which the Reporting Person is the trustee and his child is the beneficiary.
F9: Held by DJM Grantor Retained Annuity Trust No. 6 of which the Reporting Person is the trustee and the beneficiaries are The Maetzold 2018 Remainder Trust FBO John Derek Maetzold, The Maetzold 2018 Remainder Trust FBO Emily Carol Kirk, The Maetzold 2018 Remainder Trust FBO Peter Douglas Maetzold and The Maetzold 2018 Remainder Trust FBO Hannah Elizabeth Maetzold.
F10: Held by DJM Grantor Retained Annuity Trust No. 7 of which the Reporting Person is the trustee and beneficiary.
F11: Held by DJM Grantor Retained Annuity Trust No. 8 of which the Reporting Person is the trustee and beneficiary.
F12: Held by DJM Grantor Retained Annuity Trust No. 9 of which the Reporting Person is the trustee and beneficiary.
F13: The shares subject to the option are fully vested.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 04, 2022 Filed Aug 5, 2022 20:25 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 254 | $30.60 | $7,771.13 |
DisclosureSEC source: 0001447362-22-000131 · wf-form4_165973112945707.xml · nonDerivative · entry 13 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By The Maetzold 2018 Remainder Trust FBO John Derek Maetzold Disclosed balance after: 29,912 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person, The Maetzold Descendants 2020 Trust, Derek Maetzold 2020 Irrevocable Trust, The Maetzold 2018 Remainder Trust f/b/o Emily Carol Kirk, The Maetzold 2018 Remainder Trust f/b/o Hannah Elizabeth Maetzold, The Maetzold 2018 Remainder Trust f/b/o John Derek Maetzold, and The Maetzold 2018 Remainder Trust f/b/o Peter Douglas Maetzold on June 7, 2022. F9 · price: This transaction was executed in multiple trades at prices ranging from $30.000 to $30.995, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F7 · ownership.nature: Held by The Maetzold 2018 Remainder Trust FBO John Derek Maetzold of which the Reporting Person is the trustee and his child is the beneficiary. Read SEC document |
| August 04, 2022 Filed Aug 5, 2022 20:25 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 254 | $30.60 | $7,771.13 |
DisclosureSEC source: 0001447362-22-000131 · wf-form4_165973112945707.xml · nonDerivative · entry 12 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By The Maetzold 2018 Remainder Trust FBO Hannah Elizabeth Maetzold Disclosed balance after: 29,912 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person, The Maetzold Descendants 2020 Trust, Derek Maetzold 2020 Irrevocable Trust, The Maetzold 2018 Remainder Trust f/b/o Emily Carol Kirk, The Maetzold 2018 Remainder Trust f/b/o Hannah Elizabeth Maetzold, The Maetzold 2018 Remainder Trust f/b/o John Derek Maetzold, and The Maetzold 2018 Remainder Trust f/b/o Peter Douglas Maetzold on June 7, 2022. F9 · price: This transaction was executed in multiple trades at prices ranging from $30.000 to $30.995, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F6 · ownership.nature: Held by The Maetzold 2018 Remainder Trust FBO Hannah Elizabeth Maetzold of which the Reporting Person is the trustee and his child is the beneficiary. Read SEC document |
| August 04, 2022 Filed Aug 5, 2022 20:25 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 253 | $30.60 | $7,740.54 |
DisclosureSEC source: 0001447362-22-000131 · wf-form4_165973112945707.xml · nonDerivative · entry 11 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By The Maetzold 2018 Remainder Trust FBO Emily Carol Kirk Disclosed balance after: 29,914 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person, The Maetzold Descendants 2020 Trust, Derek Maetzold 2020 Irrevocable Trust, The Maetzold 2018 Remainder Trust f/b/o Emily Carol Kirk, The Maetzold 2018 Remainder Trust f/b/o Hannah Elizabeth Maetzold, The Maetzold 2018 Remainder Trust f/b/o John Derek Maetzold, and The Maetzold 2018 Remainder Trust f/b/o Peter Douglas Maetzold on June 7, 2022. F9 · price: This transaction was executed in multiple trades at prices ranging from $30.000 to $30.995, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F5 · ownership.nature: Held by The Maetzold 2018 Remainder Trust FBO Emily Carol Kirk of which the Reporting Person is the trustee and his child is the beneficiary. Read SEC document |
| August 04, 2022 Filed Aug 5, 2022 20:25 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 1,263 | $30.60 | $38,641.49 |
DisclosureSEC source: 0001447362-22-000131 · wf-form4_165973112945707.xml · nonDerivative · entry 10 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Derek Maetzold 2020 Irrevocable Trust Disclosed balance after: 134,931 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person, The Maetzold Descendants 2020 Trust, Derek Maetzold 2020 Irrevocable Trust, The Maetzold 2018 Remainder Trust f/b/o Emily Carol Kirk, The Maetzold 2018 Remainder Trust f/b/o Hannah Elizabeth Maetzold, The Maetzold 2018 Remainder Trust f/b/o John Derek Maetzold, and The Maetzold 2018 Remainder Trust f/b/o Peter Douglas Maetzold on June 7, 2022. F9 · price: This transaction was executed in multiple trades at prices ranging from $30.000 to $30.995, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F4 · ownership.nature: Held by Derek Maetzold 2020 Irrevocable Trust of which the Reporting Person is the trustee and his children are beneficiaries. Read SEC document |
| August 04, 2022 Filed Aug 5, 2022 20:25 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 1,263 | $30.60 | $38,641.49 |
DisclosureSEC source: 0001447362-22-000131 · wf-form4_165973112945707.xml · nonDerivative · entry 9 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By The Maetzold Descendants 2020 Trust Disclosed balance after: 147,408 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person, The Maetzold Descendants 2020 Trust, Derek Maetzold 2020 Irrevocable Trust, The Maetzold 2018 Remainder Trust f/b/o Emily Carol Kirk, The Maetzold 2018 Remainder Trust f/b/o Hannah Elizabeth Maetzold, The Maetzold 2018 Remainder Trust f/b/o John Derek Maetzold, and The Maetzold 2018 Remainder Trust f/b/o Peter Douglas Maetzold on June 7, 2022. F9 · price: This transaction was executed in multiple trades at prices ranging from $30.000 to $30.995, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F3 · ownership.nature: Held by The Maetzold Descendants 2020 Trust of which the Reporting Person's spouse is the trustee and the Reporting Person's spouse and their children are beneficiaries. Read SEC document |
| August 04, 2022 Filed Aug 5, 2022 20:25 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 2,526 | $30.60 | $77,282.97 |
DisclosureSEC source: 0001447362-22-000131 · wf-form4_165973112945707.xml · nonDerivative · entry 8 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 326,135 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person, The Maetzold Descendants 2020 Trust, Derek Maetzold 2020 Irrevocable Trust, The Maetzold 2018 Remainder Trust f/b/o Emily Carol Kirk, The Maetzold 2018 Remainder Trust f/b/o Hannah Elizabeth Maetzold, The Maetzold 2018 Remainder Trust f/b/o John Derek Maetzold, and The Maetzold 2018 Remainder Trust f/b/o Peter Douglas Maetzold on June 7, 2022. F9 · price: This transaction was executed in multiple trades at prices ranging from $30.000 to $30.995, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 03, 2022 Filed Aug 5, 2022 20:25 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 4 | $30.03 | $120.12 |
DisclosureSEC source: 0001447362-22-000131 · wf-form4_165973112945707.xml · nonDerivative · entry 7 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By The Maetzold 2018 Remainder Trust FBO Peter Douglas Maetzold Disclosed balance after: 30,166 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person, The Maetzold Descendants 2020 Trust, Derek Maetzold 2020 Irrevocable Trust, The Maetzold 2018 Remainder Trust f/b/o Emily Carol Kirk, The Maetzold 2018 Remainder Trust f/b/o Hannah Elizabeth Maetzold, The Maetzold 2018 Remainder Trust f/b/o John Derek Maetzold, and The Maetzold 2018 Remainder Trust f/b/o Peter Douglas Maetzold on June 7, 2022. F2 · price: This transaction was executed in multiple trades at prices ranging from $30.020 to $30.030, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F8 · ownership.nature: Held by The Maetzold 2018 Remainder Trust FBO Peter Douglas Maetzold of which the Reporting Person is the trustee and his child is the beneficiary. Read SEC document |
| August 03, 2022 Filed Aug 5, 2022 20:25 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 4 | $30.03 | $120.12 |
DisclosureSEC source: 0001447362-22-000131 · wf-form4_165973112945707.xml · nonDerivative · entry 6 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By The Maetzold 2018 Remainder Trust FBO John Derek Maetzold Disclosed balance after: 30,166 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person, The Maetzold Descendants 2020 Trust, Derek Maetzold 2020 Irrevocable Trust, The Maetzold 2018 Remainder Trust f/b/o Emily Carol Kirk, The Maetzold 2018 Remainder Trust f/b/o Hannah Elizabeth Maetzold, The Maetzold 2018 Remainder Trust f/b/o John Derek Maetzold, and The Maetzold 2018 Remainder Trust f/b/o Peter Douglas Maetzold on June 7, 2022. F2 · price: This transaction was executed in multiple trades at prices ranging from $30.020 to $30.030, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F7 · ownership.nature: Held by The Maetzold 2018 Remainder Trust FBO John Derek Maetzold of which the Reporting Person is the trustee and his child is the beneficiary. Read SEC document |
| August 03, 2022 Filed Aug 5, 2022 20:25 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 4 | $30.03 | $120.12 |
DisclosureSEC source: 0001447362-22-000131 · wf-form4_165973112945707.xml · nonDerivative · entry 5 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By The Maetzold 2018 Remainder Trust FBO Hannah Elizabeth Maetzold Disclosed balance after: 30,166 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person, The Maetzold Descendants 2020 Trust, Derek Maetzold 2020 Irrevocable Trust, The Maetzold 2018 Remainder Trust f/b/o Emily Carol Kirk, The Maetzold 2018 Remainder Trust f/b/o Hannah Elizabeth Maetzold, The Maetzold 2018 Remainder Trust f/b/o John Derek Maetzold, and The Maetzold 2018 Remainder Trust f/b/o Peter Douglas Maetzold on June 7, 2022. F2 · price: This transaction was executed in multiple trades at prices ranging from $30.020 to $30.030, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F6 · ownership.nature: Held by The Maetzold 2018 Remainder Trust FBO Hannah Elizabeth Maetzold of which the Reporting Person is the trustee and his child is the beneficiary. Read SEC document |
| August 03, 2022 Filed Aug 5, 2022 20:25 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 4 | $30.03 | $120.12 |
DisclosureSEC source: 0001447362-22-000131 · wf-form4_165973112945707.xml · nonDerivative · entry 4 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By The Maetzold 2018 Remainder Trust FBO Emily Carol Kirk Disclosed balance after: 30,167 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person, The Maetzold Descendants 2020 Trust, Derek Maetzold 2020 Irrevocable Trust, The Maetzold 2018 Remainder Trust f/b/o Emily Carol Kirk, The Maetzold 2018 Remainder Trust f/b/o Hannah Elizabeth Maetzold, The Maetzold 2018 Remainder Trust f/b/o John Derek Maetzold, and The Maetzold 2018 Remainder Trust f/b/o Peter Douglas Maetzold on June 7, 2022. F2 · price: This transaction was executed in multiple trades at prices ranging from $30.020 to $30.030, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F5 · ownership.nature: Held by The Maetzold 2018 Remainder Trust FBO Emily Carol Kirk of which the Reporting Person is the trustee and his child is the beneficiary. Read SEC document |
| August 03, 2022 Filed Aug 5, 2022 20:25 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 21 | $30.03 | $630.61 |
DisclosureSEC source: 0001447362-22-000131 · wf-form4_165973112945707.xml · nonDerivative · entry 3 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Derek Maetzold 2020 Irrevocable Trust Disclosed balance after: 136,194 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person, The Maetzold Descendants 2020 Trust, Derek Maetzold 2020 Irrevocable Trust, The Maetzold 2018 Remainder Trust f/b/o Emily Carol Kirk, The Maetzold 2018 Remainder Trust f/b/o Hannah Elizabeth Maetzold, The Maetzold 2018 Remainder Trust f/b/o John Derek Maetzold, and The Maetzold 2018 Remainder Trust f/b/o Peter Douglas Maetzold on June 7, 2022. F2 · price: This transaction was executed in multiple trades at prices ranging from $30.020 to $30.030, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F4 · ownership.nature: Held by Derek Maetzold 2020 Irrevocable Trust of which the Reporting Person is the trustee and his children are beneficiaries. Read SEC document |
| August 03, 2022 Filed Aug 5, 2022 20:25 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 21 | $30.03 | $630.61 |
DisclosureSEC source: 0001447362-22-000131 · wf-form4_165973112945707.xml · nonDerivative · entry 2 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By The Maetzold Descendants 2020 Trust Disclosed balance after: 148,671 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person, The Maetzold Descendants 2020 Trust, Derek Maetzold 2020 Irrevocable Trust, The Maetzold 2018 Remainder Trust f/b/o Emily Carol Kirk, The Maetzold 2018 Remainder Trust f/b/o Hannah Elizabeth Maetzold, The Maetzold 2018 Remainder Trust f/b/o John Derek Maetzold, and The Maetzold 2018 Remainder Trust f/b/o Peter Douglas Maetzold on June 7, 2022. F2 · price: This transaction was executed in multiple trades at prices ranging from $30.020 to $30.030, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F3 · ownership.nature: Held by The Maetzold Descendants 2020 Trust of which the Reporting Person's spouse is the trustee and the Reporting Person's spouse and their children are beneficiaries. Read SEC document |
| August 03, 2022 Filed Aug 5, 2022 20:25 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 42 | $30.03 | $1,261.22 |
DisclosureSEC source: 0001447362-22-000131 · wf-form4_165973112945707.xml · nonDerivative · entry 1 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 328,661 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person, The Maetzold Descendants 2020 Trust, Derek Maetzold 2020 Irrevocable Trust, The Maetzold 2018 Remainder Trust f/b/o Emily Carol Kirk, The Maetzold 2018 Remainder Trust f/b/o Hannah Elizabeth Maetzold, The Maetzold 2018 Remainder Trust f/b/o John Derek Maetzold, and The Maetzold 2018 Remainder Trust f/b/o Peter Douglas Maetzold on June 7, 2022. F2 · price: This transaction was executed in multiple trades at prices ranging from $30.020 to $30.030, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 02, 2022 Filed Aug 3, 2022 21:06 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 11 | $27.12 | $298.34 |
DisclosureSEC source: 0001447362-22-000129 · wf-form4_165956079250648.xml · nonDerivative · entry 14 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By The Maetzold 2018 Remainder Trust FBO Peter Douglas Maetzold Disclosed balance after: 30,170 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person, The Maetzold Descendants 2020 Trust, Derek Maetzold 2020 Irrevocable Trust, The Maetzold 2018 Remainder Trust f/b/o Emily Carol Kirk, The Maetzold 2018 Remainder Trust f/b/o Hannah Elizabeth Maetzold, The Maetzold 2018 Remainder Trust f/b/o John Derek Maetzold, and The Maetzold 2018 Remainder Trust f/b/o Peter Douglas Maetzold on June 7, 2022. F10 · price: This transaction was executed in multiple trades at prices ranging from $27.060 to $27.210, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F9 · ownership.nature: Held by The Maetzold 2018 Remainder Trust FBO Peter Douglas Maetzold of which the Reporting Person is the trustee and his child is the beneficiary. Read SEC document |
| August 02, 2022 Filed Aug 3, 2022 21:06 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 11 | $27.12 | $298.34 |
DisclosureSEC source: 0001447362-22-000129 · wf-form4_165956079250648.xml · nonDerivative · entry 13 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By The Maetzold 2018 Remainder Trust FBO John Derek Maetzold Disclosed balance after: 30,170 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person, The Maetzold Descendants 2020 Trust, Derek Maetzold 2020 Irrevocable Trust, The Maetzold 2018 Remainder Trust f/b/o Emily Carol Kirk, The Maetzold 2018 Remainder Trust f/b/o Hannah Elizabeth Maetzold, The Maetzold 2018 Remainder Trust f/b/o John Derek Maetzold, and The Maetzold 2018 Remainder Trust f/b/o Peter Douglas Maetzold on June 7, 2022. F10 · price: This transaction was executed in multiple trades at prices ranging from $27.060 to $27.210, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F8 · ownership.nature: Held by The Maetzold 2018 Remainder Trust FBO John Derek Maetzold of which the Reporting Person is the trustee and his child is the beneficiary. Read SEC document |
| August 02, 2022 Filed Aug 3, 2022 21:06 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 11 | $27.12 | $298.34 |
DisclosureSEC source: 0001447362-22-000129 · wf-form4_165956079250648.xml · nonDerivative · entry 12 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By The Maetzold 2018 Remainder Trust FBO Hannah Elizabeth Maetzold Disclosed balance after: 30,170 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person, The Maetzold Descendants 2020 Trust, Derek Maetzold 2020 Irrevocable Trust, The Maetzold 2018 Remainder Trust f/b/o Emily Carol Kirk, The Maetzold 2018 Remainder Trust f/b/o Hannah Elizabeth Maetzold, The Maetzold 2018 Remainder Trust f/b/o John Derek Maetzold, and The Maetzold 2018 Remainder Trust f/b/o Peter Douglas Maetzold on June 7, 2022. F10 · price: This transaction was executed in multiple trades at prices ranging from $27.060 to $27.210, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F7 · ownership.nature: Held by The Maetzold 2018 Remainder Trust FBO Hannah Elizabeth Maetzold of which the Reporting Person is the trustee and his child is the beneficiary. Read SEC document |
| August 02, 2022 Filed Aug 3, 2022 21:06 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 10 | $27.12 | $271.22 |
DisclosureSEC source: 0001447362-22-000129 · wf-form4_165956079250648.xml · nonDerivative · entry 11 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By The Maetzold 2018 Remainder Trust FBO Emily Carol Kirk Disclosed balance after: 30,171 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person, The Maetzold Descendants 2020 Trust, Derek Maetzold 2020 Irrevocable Trust, The Maetzold 2018 Remainder Trust f/b/o Emily Carol Kirk, The Maetzold 2018 Remainder Trust f/b/o Hannah Elizabeth Maetzold, The Maetzold 2018 Remainder Trust f/b/o John Derek Maetzold, and The Maetzold 2018 Remainder Trust f/b/o Peter Douglas Maetzold on June 7, 2022. F10 · price: This transaction was executed in multiple trades at prices ranging from $27.060 to $27.210, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F6 · ownership.nature: Held by The Maetzold 2018 Remainder Trust FBO Emily Carol Kirk of which the Reporting Person is the trustee and his child is the beneficiary. Read SEC document |
| August 02, 2022 Filed Aug 3, 2022 21:06 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 51 | $27.12 | $1,383.22 |
DisclosureSEC source: 0001447362-22-000129 · wf-form4_165956079250648.xml · nonDerivative · entry 10 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Derek Maetzold 2020 Irrevocable Trust Disclosed balance after: 136,215 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person, The Maetzold Descendants 2020 Trust, Derek Maetzold 2020 Irrevocable Trust, The Maetzold 2018 Remainder Trust f/b/o Emily Carol Kirk, The Maetzold 2018 Remainder Trust f/b/o Hannah Elizabeth Maetzold, The Maetzold 2018 Remainder Trust f/b/o John Derek Maetzold, and The Maetzold 2018 Remainder Trust f/b/o Peter Douglas Maetzold on June 7, 2022. F10 · price: This transaction was executed in multiple trades at prices ranging from $27.060 to $27.210, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F5 · ownership.nature: Held by Derek Maetzold 2020 Irrevocable Trust of which the Reporting Person is the trustee and his children are beneficiaries. Read SEC document |
| August 02, 2022 Filed Aug 3, 2022 21:06 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 54 | $27.12 | $1,464.59 |
DisclosureSEC source: 0001447362-22-000129 · wf-form4_165956079250648.xml · nonDerivative · entry 9 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By The Maetzold Descendants 2020 Trust Disclosed balance after: 148,692 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person, The Maetzold Descendants 2020 Trust, Derek Maetzold 2020 Irrevocable Trust, The Maetzold 2018 Remainder Trust f/b/o Emily Carol Kirk, The Maetzold 2018 Remainder Trust f/b/o Hannah Elizabeth Maetzold, The Maetzold 2018 Remainder Trust f/b/o John Derek Maetzold, and The Maetzold 2018 Remainder Trust f/b/o Peter Douglas Maetzold on June 7, 2022. F10 · price: This transaction was executed in multiple trades at prices ranging from $27.060 to $27.210, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F4 · ownership.nature: Held by The Maetzold Descendants 2020 Trust of which the Reporting Person's spouse is the trustee and the Reporting Person's spouse and their children are beneficiaries. Read SEC document |
| August 02, 2022 Filed Aug 3, 2022 21:06 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 111 | $27.12 | $3,010.54 |
DisclosureSEC source: 0001447362-22-000129 · wf-form4_165956079250648.xml · nonDerivative · entry 8 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 328,703 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person, The Maetzold Descendants 2020 Trust, Derek Maetzold 2020 Irrevocable Trust, The Maetzold 2018 Remainder Trust f/b/o Emily Carol Kirk, The Maetzold 2018 Remainder Trust f/b/o Hannah Elizabeth Maetzold, The Maetzold 2018 Remainder Trust f/b/o John Derek Maetzold, and The Maetzold 2018 Remainder Trust f/b/o Peter Douglas Maetzold on June 7, 2022. F10 · price: This transaction was executed in multiple trades at prices ranging from $27.060 to $27.210, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 01, 2022 Filed Aug 3, 2022 21:06 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 364 | $27.44 | $9,987.80 |
DisclosureSEC source: 0001447362-22-000129 · wf-form4_165956079250648.xml · nonDerivative · entry 7 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By The Maetzold 2018 Remainder Trust FBO Peter Douglas Maetzold Disclosed balance after: 30,181 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person, The Maetzold Descendants 2020 Trust, Derek Maetzold 2020 Irrevocable Trust, The Maetzold 2018 Remainder Trust f/b/o Emily Carol Kirk, The Maetzold 2018 Remainder Trust f/b/o Hannah Elizabeth Maetzold, The Maetzold 2018 Remainder Trust f/b/o John Derek Maetzold, and The Maetzold 2018 Remainder Trust f/b/o Peter Douglas Maetzold on June 7, 2022. F2 · price: This transaction was executed in multiple trades at prices ranging from $27.055 to $27.950, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F9 · ownership.nature: Held by The Maetzold 2018 Remainder Trust FBO Peter Douglas Maetzold of which the Reporting Person is the trustee and his child is the beneficiary. Read SEC document |
| August 01, 2022 Filed Aug 3, 2022 21:06 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 364 | $27.44 | $9,987.80 |
DisclosureSEC source: 0001447362-22-000129 · wf-form4_165956079250648.xml · nonDerivative · entry 6 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By The Maetzold 2018 Remainder Trust FBO John Derek Maetzold Disclosed balance after: 30,181 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person, The Maetzold Descendants 2020 Trust, Derek Maetzold 2020 Irrevocable Trust, The Maetzold 2018 Remainder Trust f/b/o Emily Carol Kirk, The Maetzold 2018 Remainder Trust f/b/o Hannah Elizabeth Maetzold, The Maetzold 2018 Remainder Trust f/b/o John Derek Maetzold, and The Maetzold 2018 Remainder Trust f/b/o Peter Douglas Maetzold on June 7, 2022. F2 · price: This transaction was executed in multiple trades at prices ranging from $27.055 to $27.950, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F8 · ownership.nature: Held by The Maetzold 2018 Remainder Trust FBO John Derek Maetzold of which the Reporting Person is the trustee and his child is the beneficiary. Read SEC document |
| August 01, 2022 Filed Aug 3, 2022 21:06 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 364 | $27.44 | $9,987.80 |
DisclosureSEC source: 0001447362-22-000129 · wf-form4_165956079250648.xml · nonDerivative · entry 5 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By The Maetzold 2018 Remainder Trust FBO Hannah Elizabeth Maetzold Disclosed balance after: 30,181 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person, The Maetzold Descendants 2020 Trust, Derek Maetzold 2020 Irrevocable Trust, The Maetzold 2018 Remainder Trust f/b/o Emily Carol Kirk, The Maetzold 2018 Remainder Trust f/b/o Hannah Elizabeth Maetzold, The Maetzold 2018 Remainder Trust f/b/o John Derek Maetzold, and The Maetzold 2018 Remainder Trust f/b/o Peter Douglas Maetzold on June 7, 2022. F2 · price: This transaction was executed in multiple trades at prices ranging from $27.055 to $27.950, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F7 · ownership.nature: Held by The Maetzold 2018 Remainder Trust FBO Hannah Elizabeth Maetzold of which the Reporting Person is the trustee and his child is the beneficiary. Read SEC document |
| August 01, 2022 Filed Aug 3, 2022 21:06 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 365 | $27.44 | $10,015.24 |
DisclosureSEC source: 0001447362-22-000129 · wf-form4_165956079250648.xml · nonDerivative · entry 4 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By The Maetzold 2018 Remainder Trust FBO Emily Carol Kirk Disclosed balance after: 30,181 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person, The Maetzold Descendants 2020 Trust, Derek Maetzold 2020 Irrevocable Trust, The Maetzold 2018 Remainder Trust f/b/o Emily Carol Kirk, The Maetzold 2018 Remainder Trust f/b/o Hannah Elizabeth Maetzold, The Maetzold 2018 Remainder Trust f/b/o John Derek Maetzold, and The Maetzold 2018 Remainder Trust f/b/o Peter Douglas Maetzold on June 7, 2022. F2 · price: This transaction was executed in multiple trades at prices ranging from $27.055 to $27.950, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F6 · ownership.nature: Held by The Maetzold 2018 Remainder Trust FBO Emily Carol Kirk of which the Reporting Person is the trustee and his child is the beneficiary. Read SEC document |
| August 01, 2022 Filed Aug 3, 2022 21:06 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 1,699 | $27.44 | $46,618.86 |
DisclosureSEC source: 0001447362-22-000129 · wf-form4_165956079250648.xml · nonDerivative · entry 3 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Derek Maetzold 2020 Irrevocable Trust Disclosed balance after: 136,266 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person, The Maetzold Descendants 2020 Trust, Derek Maetzold 2020 Irrevocable Trust, The Maetzold 2018 Remainder Trust f/b/o Emily Carol Kirk, The Maetzold 2018 Remainder Trust f/b/o Hannah Elizabeth Maetzold, The Maetzold 2018 Remainder Trust f/b/o John Derek Maetzold, and The Maetzold 2018 Remainder Trust f/b/o Peter Douglas Maetzold on June 7, 2022. F2 · price: This transaction was executed in multiple trades at prices ranging from $27.055 to $27.950, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F5 · ownership.nature: Held by Derek Maetzold 2020 Irrevocable Trust of which the Reporting Person is the trustee and his children are beneficiaries. Read SEC document |
| August 01, 2022 Filed Aug 3, 2022 21:06 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 1,821 | $27.44 | $49,966.42 |
DisclosureSEC source: 0001447362-22-000129 · wf-form4_165956079250648.xml · nonDerivative · entry 2 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By The Maetzold Descendants 2020 Trust Disclosed balance after: 148,746 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person, The Maetzold Descendants 2020 Trust, Derek Maetzold 2020 Irrevocable Trust, The Maetzold 2018 Remainder Trust f/b/o Emily Carol Kirk, The Maetzold 2018 Remainder Trust f/b/o Hannah Elizabeth Maetzold, The Maetzold 2018 Remainder Trust f/b/o John Derek Maetzold, and The Maetzold 2018 Remainder Trust f/b/o Peter Douglas Maetzold on June 7, 2022. F2 · price: This transaction was executed in multiple trades at prices ranging from $27.055 to $27.950, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F4 · ownership.nature: Held by The Maetzold Descendants 2020 Trust of which the Reporting Person's spouse is the trustee and the Reporting Person's spouse and their children are beneficiaries. Read SEC document |
| August 01, 2022 Filed Aug 3, 2022 21:06 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 3,723 | $27.44 | $102,155.40 |
DisclosureSEC source: 0001447362-22-000129 · wf-form4_165956079250648.xml · nonDerivative · entry 1 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 328,814 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person, The Maetzold Descendants 2020 Trust, Derek Maetzold 2020 Irrevocable Trust, The Maetzold 2018 Remainder Trust f/b/o Emily Carol Kirk, The Maetzold 2018 Remainder Trust f/b/o Hannah Elizabeth Maetzold, The Maetzold 2018 Remainder Trust f/b/o John Derek Maetzold, and The Maetzold 2018 Remainder Trust f/b/o Peter Douglas Maetzold on June 7, 2022. F2 · price: This transaction was executed in multiple trades at prices ranging from $27.055 to $27.950, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F3 · balance_after: On May 26, 2022, the Reporting Person transferred 55,603 shares of Castle Biosciences, Inc. common stock from DJM Grantor Retained Annuity Trust No. 2 and 75,000 shares from DJM Grantor Retained Annuity Trust No. 3 to his direct holdings. Read SEC document |
| April 26, 2022 Filed Apr 28, 2022 23:29 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | GrantCommon Stock | 22,311 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001447362-22-000068 · wf-form4_165118849087804.xml · nonDerivative · entry 1 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 201,934 F1 · shares: The reporting person acquired 22,311 shares of common stock on April 26, 2022, as consideration for the Reporting Person's equity securities of AltheaDx, Inc. ("AltheaDx"), which Castle Biosciences, Inc. ("Castle Biosciences") acquired by merger on April 26, 2022 (the "Merger") pursuant to an Agreement and Plan of Merger agreement dated April 4, 2022 (the "Merger Agreement"). Of the 22,311 shares issued to the Reporting Person in the Merger, 1,895 shares are currently being held in escrow and are subject to forfeiture for a specified period following the Merger to satisfy indemnification claims arising of Castle Biosciences, if any. F2 · shares: The Merger Agreement provides that the former securityholders of AltheaDx may receive additional consideration, payable 50% in cash and 50% in shares of common stock of Castle Biosciences, based on the achievement of certain commercial milestones with related dates or performance periods through December 31, 2024 (the "Milestone Payments"). The portion of the Milestone Payments payable in shares of common stock will be valued at the volume-weighted average price for the 20 trading days ending as of the applicable determination date. The number of shares issuable is subject to certain limitations set forth in the Merger Agreement. The Reporting Person's right to receive additional shares pursuant to this earn-out right became fixed and irrevocable on April 26, 2022, the effective date of the merger. F3 · price: The number of shares issuable was determined pursuant to a formula set forth in the Merger Agreement, which provided that, for the purpose of determining the number of shares issuable, the shares of Castle Biosciences common stock would be valued at $42.54, which represents the volume weighted average share price of the stock for the 20 trading days immediately preceding the date of the Merger Agreement. F4 · balance_after: On March 2, 2022, and March 3, 2022, the DJM Grantor Retained Annuity Trust No. 2 made annuity payments to the Reporting Person by transferring a total of 44,397 shares of Castle Biosciences, Inc. common stock to his direct holdings. Read SEC document |
| January 10, 2022 Filed Jan 20, 2022 22:16 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | GiftCommon Stock | 122,181 | $0.00 | $0.00 |
DisclosureSEC source: 0001447362-22-000018 · wf-form4_164271698171877.xml · nonDerivative · entry 1 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By DJM Grantor Retained Annuity Trust No. 1 Disclosed balance after: 0 F1 · balance_after: On January 5, 2022, the Reporting Person transferred 5,547 shares of Castle Biosciences, Inc. common stock to his direct holdings. F2 · balance_after: On January 10, 2022, the Reporting Person transferred 122,181 shares collectively of Castle Biosciences, Inc. common stock to The Maetzold 2018 Remainder Trust FBO Hannah Elizabeth Maetzold, The Maetzold 2018 Remainder Trust FBO Peter Douglas Maetzold, The Maetzold 2018 Remainder Trust FBO Emily Carol Kirk, and The Maetzold 2018 Remainder Trust FBO John Derek Maetzold, all of which the Reporting Person is the trustee and his children are the beneficiaries. Read SEC document |
| December 10, 2021 Filed Dec 15, 2021 00:56 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | Exercise / conversionRestricted Stock Units · Derivative | 5,363 | $0.00 | $0.00 |
DisclosureSEC source: 0001447362-21-000266 · wf-form4_163952979508094.xml · derivative · entry 9 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,087 Underlying: Common Stock · 5,363 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock. F8 · derivative.exercise_date: On December 10, 2020, the Reporting Person was granted 21,450 RSUs, which vest in four equal annual installments beginning on December 10, 2021. F8 · derivative.expiration_date: On December 10, 2020, the Reporting Person was granted 21,450 RSUs, which vest in four equal annual installments beginning on December 10, 2021. Read SEC document |
| December 10, 2021 Filed Dec 15, 2021 00:56 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | GrantRestricted Stock Units · Derivative | 61,698 | $0.00 | $0.00 |
DisclosureSEC source: 0001447362-21-000266 · wf-form4_163952979508094.xml · derivative · entry 8 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,698 Underlying: Common Stock · 61,698 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock. F7 · derivative.exercise_date: The RSUs vest in four equal annual installments beginning on December 10, 2022. F7 · derivative.expiration_date: The RSUs vest in four equal annual installments beginning on December 10, 2022. Read SEC document |
| December 10, 2021 Filed Dec 15, 2021 00:56 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | GrantStock option (right to buy) · Derivative | 106,376 | $0.00 Strike: $40.52 | $0.00 |
DisclosureSEC source: 0001447362-21-000266 · wf-form4_163952979508094.xml · derivative · entry 7 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,376 Underlying: Common Stock · 106,376 shares Expires 2031-12-09 F6 · derivative.exercise_date: 25% of shares shall vest on December 10, 2022, and the remaining shares shall vest in 36 equal monthly installments thereafter. Read SEC document |
| December 10, 2021 Filed Dec 15, 2021 00:56 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | Tax withholdingCommon Stock | 2,111 | $40.52 | $85,537.72 |
DisclosureSEC source: 0001447362-21-000266 · wf-form4_163952979508094.xml · nonDerivative · entry 2 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 229,679 Read SEC document |
| December 10, 2021 Filed Dec 15, 2021 00:56 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | Exercise / conversionCommon Stock | 5,363 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001447362-21-000266 · wf-form4_163952979508094.xml · nonDerivative · entry 1 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 231,790 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock. F2 · balance_after: On December 9, 2021, the Reporting Person transferred 75,000 shares of Castle Biosciences, Inc. common stock to the DJM Grantor Retained Annuity Trust No. 3 of which the Reporting Person is trustee and beneficiary. Read SEC document |
| November 16, 2021 Filed Nov 17, 2021 23:08 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | Exercise / conversionStock option (right to buy) · Derivative | 15,409 | $0.00 Strike: $3.72 | $0.00 |
DisclosureSEC source: 0001447362-21-000259 · wf-form4_163719045708152.xml · derivative · entry 9 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,686 Underlying: Common Stock · 15,409 shares Expires 2024-03-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The shares subject to the option are fully vested. Read SEC document |
| November 16, 2021 Filed Nov 17, 2021 23:08 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | Exercise / conversionCommon Stock | 15,409 | $3.72 | $57,321.48 |
DisclosureSEC source: 0001447362-21-000259 · wf-form4_163719045708152.xml · nonDerivative · entry 4 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 301,427 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 15, 2021 Filed Nov 17, 2021 23:08 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | Exercise / conversionStock option (right to buy) · Derivative | 16,406 | $0.00 Strike: $2.36 | $0.00 |
DisclosureSEC source: 0001447362-21-000259 · wf-form4_163719045708152.xml · derivative · entry 8 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 16,406 shares Expires 2022-07-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The shares subject to the option are fully vested. Read SEC document |
| November 15, 2021 Filed Nov 17, 2021 23:08 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 1,012 | $53.04 | $53,678.50 |
DisclosureSEC source: 0001447362-21-000259 · wf-form4_163719045708152.xml · nonDerivative · entry 3 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 286,018 F2 · price: This transaction was executed in multiple trades at prices ranging from $53.000 to $53.170, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 15, 2021 Filed Nov 17, 2021 23:08 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 15,394 | $52.47 | $807,784.76 |
DisclosureSEC source: 0001447362-21-000259 · wf-form4_163719045708152.xml · nonDerivative · entry 2 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 287,030 F1 · price: This transaction was executed in multiple trades at prices ranging from $52.000 to $52.995, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 15, 2021 Filed Nov 17, 2021 23:08 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | Exercise / conversionCommon Stock | 16,406 | $2.36 | $38,718.16 |
DisclosureSEC source: 0001447362-21-000259 · wf-form4_163719045708152.xml · nonDerivative · entry 1 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 302,424 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 10, 2021 Filed Nov 12, 2021 21:38 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 34 | $57.26 | $1,946.84 |
DisclosureSEC source: 0001447362-21-000257 · wf-form4_163675307684218.xml · nonDerivative · entry 21 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Derek Maetzold 2020 Irrevocable Trust Disclosed balance after: 137,965 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by DJM Grantor Retained Annuity Trust No. 1, The Maetzold Descendants 2020 Trust, and the Derek Maetzold 2020 Irrevocable Trust on June 15, 2021. F8 · ownership.nature: Held by Derek Maetzold 2020 Irrevocable Trust of which the Reporting Person is the trustee and his children are beneficiaries. Read SEC document |
| November 10, 2021 Filed Nov 12, 2021 21:38 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 233 | $56.52 | $13,168.46 |
DisclosureSEC source: 0001447362-21-000257 · wf-form4_163675307684218.xml · nonDerivative · entry 20 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Derek Maetzold 2020 Irrevocable Trust Disclosed balance after: 137,999 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by DJM Grantor Retained Annuity Trust No. 1, The Maetzold Descendants 2020 Trust, and the Derek Maetzold 2020 Irrevocable Trust on June 15, 2021. F10 · price: This transaction was executed in multiple trades at prices ranging from $56.180 to $57.020, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F8 · ownership.nature: Held by Derek Maetzold 2020 Irrevocable Trust of which the Reporting Person is the trustee and his children are beneficiaries. Read SEC document |
| November 10, 2021 Filed Nov 12, 2021 21:38 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 133 | $55.59 | $7,393.87 |
DisclosureSEC source: 0001447362-21-000257 · wf-form4_163675307684218.xml · nonDerivative · entry 19 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Derek Maetzold 2020 Irrevocable Trust Disclosed balance after: 138,232 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by DJM Grantor Retained Annuity Trust No. 1, The Maetzold Descendants 2020 Trust, and the Derek Maetzold 2020 Irrevocable Trust on June 15, 2021. F9 · price: This transaction was executed in multiple trades at prices ranging from $55.060 to $55.950, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F8 · ownership.nature: Held by Derek Maetzold 2020 Irrevocable Trust of which the Reporting Person is the trustee and his children are beneficiaries. Read SEC document |
| November 10, 2021 Filed Nov 12, 2021 21:38 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 33 | $57.26 | $1,889.58 |
DisclosureSEC source: 0001447362-21-000257 · wf-form4_163675307684218.xml · nonDerivative · entry 18 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By The Maetzold Descendants 2020 Trust Disclosed balance after: 150,567 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by DJM Grantor Retained Annuity Trust No. 1, The Maetzold Descendants 2020 Trust, and the Derek Maetzold 2020 Irrevocable Trust on June 15, 2021. F7 · ownership.nature: Held by The Maetzold Descendants 2020 Trust of which the Reporting Person's spouse is the trustee and the Reporting Person's spouse and their children are beneficiaries. Read SEC document |
| November 10, 2021 Filed Nov 12, 2021 21:38 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 234 | $56.52 | $13,224.98 |
DisclosureSEC source: 0001447362-21-000257 · wf-form4_163675307684218.xml · nonDerivative · entry 17 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By The Maetzold Descendants 2020 Trust Disclosed balance after: 150,600 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by DJM Grantor Retained Annuity Trust No. 1, The Maetzold Descendants 2020 Trust, and the Derek Maetzold 2020 Irrevocable Trust on June 15, 2021. F10 · price: This transaction was executed in multiple trades at prices ranging from $56.180 to $57.020, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F7 · ownership.nature: Held by The Maetzold Descendants 2020 Trust of which the Reporting Person's spouse is the trustee and the Reporting Person's spouse and their children are beneficiaries. Read SEC document |
| November 10, 2021 Filed Nov 12, 2021 21:38 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 133 | $55.59 | $7,393.87 |
DisclosureSEC source: 0001447362-21-000257 · wf-form4_163675307684218.xml · nonDerivative · entry 16 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By The Maetzold Descendants 2020 Trust Disclosed balance after: 150,834 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by DJM Grantor Retained Annuity Trust No. 1, The Maetzold Descendants 2020 Trust, and the Derek Maetzold 2020 Irrevocable Trust on June 15, 2021. F9 · price: This transaction was executed in multiple trades at prices ranging from $55.060 to $55.950, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F7 · ownership.nature: Held by The Maetzold Descendants 2020 Trust of which the Reporting Person's spouse is the trustee and the Reporting Person's spouse and their children are beneficiaries. Read SEC document |
| November 10, 2021 Filed Nov 12, 2021 21:38 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 33 | $57.26 | $1,889.58 |
DisclosureSEC source: 0001447362-21-000257 · wf-form4_163675307684218.xml · nonDerivative · entry 15 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By DJM Grantor Retained Annuity Trust No. 1 Disclosed balance after: 127,728 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by DJM Grantor Retained Annuity Trust No. 1, The Maetzold Descendants 2020 Trust, and the Derek Maetzold 2020 Irrevocable Trust on June 15, 2021. F3 · ownership.nature: Held by DJM Grantor Retained Annuity Trust No. 1 of which the Reporting Person is the trustee and beneficiary. Read SEC document |
| November 10, 2021 Filed Nov 12, 2021 21:38 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 233 | $56.52 | $13,168.46 |
DisclosureSEC source: 0001447362-21-000257 · wf-form4_163675307684218.xml · nonDerivative · entry 14 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By DJM Grantor Retained Annuity Trust No. 1 Disclosed balance after: 127,761 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by DJM Grantor Retained Annuity Trust No. 1, The Maetzold Descendants 2020 Trust, and the Derek Maetzold 2020 Irrevocable Trust on June 15, 2021. F10 · price: This transaction was executed in multiple trades at prices ranging from $56.180 to $57.020, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F3 · ownership.nature: Held by DJM Grantor Retained Annuity Trust No. 1 of which the Reporting Person is the trustee and beneficiary. Read SEC document |
| November 10, 2021 Filed Nov 12, 2021 21:38 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 134 | $55.59 | $7,449.46 |
DisclosureSEC source: 0001447362-21-000257 · wf-form4_163675307684218.xml · nonDerivative · entry 13 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By DJM Grantor Retained Annuity Trust No. 1 Disclosed balance after: 127,994 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by DJM Grantor Retained Annuity Trust No. 1, The Maetzold Descendants 2020 Trust, and the Derek Maetzold 2020 Irrevocable Trust on June 15, 2021. F9 · price: This transaction was executed in multiple trades at prices ranging from $55.060 to $55.950, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F3 · ownership.nature: Held by DJM Grantor Retained Annuity Trust No. 1 of which the Reporting Person is the trustee and beneficiary. Read SEC document |
| November 09, 2021 Filed Nov 12, 2021 21:38 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 200 | $59.09 | $11,818.80 |
DisclosureSEC source: 0001447362-21-000257 · wf-form4_163675307684218.xml · nonDerivative · entry 12 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Derek Maetzold 2020 Irrevocable Trust Disclosed balance after: 138,365 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by DJM Grantor Retained Annuity Trust No. 1, The Maetzold Descendants 2020 Trust, and the Derek Maetzold 2020 Irrevocable Trust on June 15, 2021. F6 · price: This transaction was executed in multiple trades at prices ranging from $58.540 to $59.375, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F8 · ownership.nature: Held by Derek Maetzold 2020 Irrevocable Trust of which the Reporting Person is the trustee and his children are beneficiaries. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.